Jardiance for Adolescents (Ages 12 to 17): Caregiver Administration Guidance

Why the FDA Approved Jardiance for Adolescents

The FDA extended empagliflozin's indication to patients aged 12 to 17 with type 2 diabetes (T2D) in June 2023, based on pharmacokinetic modeling and safety data from pediatric studies. [1] This made empagliflozin one of only a handful of non-insulin, non-metformin agents with formal regulatory approval for adolescent T2D.

Type 2 diabetes in adolescents is a growing clinical problem. The TODAY2 follow-up study found that more than 67% of youth-onset T2D participants developed at least one comorbidity within 15 years of diagnosis. [2] Earlier pharmacologic intervention with agents that carry both glucose-lowering and cardiorenal benefits has become a research and clinical priority.

What the Pediatric Pharmacokinetic Data Show

The approval was supported by a population pharmacokinetic analysis comparing drug exposure in adolescents to adults. The analysis confirmed that a 10 mg once-daily dose in adolescents aged 12 to 17 produces area-under-the-curve (AUC) exposures that overlap with those seen in adults receiving the same dose, the dose range already proven effective in the adult EMPA-REG OUTCOME trial (N=7,020). [3]

The FDA label states that no dose adjustment is needed based on age alone in this population, provided renal function is adequate. [1]

How Empagliflozin Works in a Teenager's Body

Empagliflozin blocks SGLT2 receptors in the proximal renal tubule, preventing roughly 90 grams of glucose per day from being reabsorbed, and instead flushing it out through urine. [4] This mechanism does not depend on insulin secretion, which matters in adolescent T2D because beta-cell function declines faster in youth-onset disease than in adult-onset disease, according to the TODAY study group. [5]

The glucose-lowering effect is therefore preserved even as endogenous insulin secretion wanes over time.

The Correct Dose for Adolescents Aged 12 to 17

The approved starting dose of empagliflozin for adolescents is 10 mg orally once daily, taken in the morning. The prescriber may increase the dose to 25 mg once daily if additional glycemic control is needed and the teen is tolerating 10 mg without significant adverse effects. [1]

Caregivers should not make dose changes independently. The increase from 10 mg to 25 mg must be directed by the prescribing clinician after reviewing the teen's hemoglobin A1c (HbA1c), blood glucose logs, and kidney function.

Morning Dosing and Why Timing Matters

Taking the dose in the morning minimizes nocturnal urinary frequency, which can disrupt sleep and lead to accidental non-adherence (the teen wakes up uncomfortable and starts skipping doses). The FDA label specifies morning administration for exactly this reason. [1]

Consistency matters more than the precise clock time. A dose taken at 7:30 a.m. On school days and 9:00 a.m. On weekends still provides adequate 24-hour SGLT2 inhibition, given empagliflozin's terminal half-life of approximately 12.4 hours. [1]

Can the Tablet Be Split or Crushed?

The prescribing information does not list empagliflozin tablets as extended-release formulations, and they are not film-coated for delayed absorption. Splitting is technically possible if the teen struggles to swallow tablets whole, but caregivers should confirm this with the dispensing pharmacist first, because tablet-splitting alters the dose slightly and may affect ease of swallowing without meaningful pharmacokinetic consequence.

Crushing and mixing with food or liquid is not addressed in the FDA label and should be avoided without explicit pharmacist or prescriber guidance. [1]

Food, Drink, and Timing Considerations

Empagliflozin can be taken with or without food. No meal timing restriction appears in the FDA prescribing information. [1] A small 2014 pharmacokinetic study (N=48 healthy adults) showed that a high-fat, high-calorie meal slowed the rate of absorption slightly (Tmax shifted from 1.5 hours to 3 hours) but did not change overall drug exposure (AUC). [4] Caregivers do not need to prepare a special meal around the dose.

Beverages and Hydration

Because empagliflozin increases urinary glucose excretion and osmotic water loss, adequate hydration throughout the day is important. The teen should drink enough water to keep urine light yellow. Sugary sports drinks and fruit juices raise blood glucose and may blunt the drug's effect.

Alcohol is worth a separate discussion with the prescriber. Teenagers legally should not drink, but the clinical reality warrants mentioning that alcohol combined with SGLT2 inhibitors may increase the risk of euglycemic diabetic ketoacidosis (DKA) by reducing hepatic gluconeogenesis and promoting ketogenesis. [6]

Grapefruit and Drug Interactions

Grapefruit does not interact with empagliflozin. The drug is primarily metabolized via UGT1A3, UGT1A8, UGT1A9, and UGT2B7 glucuronidation pathways, not CYP3A4, so the grapefruit-CYP3A4 interaction that complicates many other medications does not apply here. [1]

Diuretics (thiazides, loop diuretics) and lithium are the combinations caregivers should specifically flag for the prescriber, as these can compound volume depletion or alter lithium clearance. [1]

What Caregivers Should Watch For: Side Effects in Adolescents

The most common adverse effects reported in clinical studies were genital mycotic infections and urinary tract infections (UTIs), consistent with the adult experience. The increased urinary glucose creates a growth medium for Candida and bacteria.

Genital Mycotic Infections

In adult trials, genital mycotic infections occurred in approximately 6.4% of women and 3.1% of men taking empagliflozin 10 mg versus 0.9% and 0.6% on placebo, respectively. [3] Adolescent-specific rates have not been published in a large pediatric RCT, but the mechanism is identical.

Caregivers should instruct the teen to:

• Wipe front-to-back after using the bathroom.
• Change out of damp swimwear or athletic clothing promptly.
• Report itching, redness, unusual discharge, or discomfort in the genital area.

A first episode of uncomplicated genital yeast infection does not automatically require stopping empagliflozin. The prescriber can treat the infection and reassess.

Urinary Tract Infections

Symptoms to watch for include burning or pain during urination, frequent urge to urinate beyond the expected drug-related polyuria, cloudy or foul-smelling urine, and lower abdominal pain. Fever and back/flank pain suggest a possible kidney infection (pyelonephritis) and warrant same-day medical evaluation. [7]

Dehydration and Volume Depletion

Osmotic diuresis from glucosuria can cause mild dehydration, particularly in hot weather, during illness, or with intense athletic activity. Signs include dizziness on standing, dry mouth, and decreased urine output after initial polyuria.

Caregivers of athletes should discuss temporary dose holds during prolonged heat exposure or gastrointestinal illness with the prescriber. The FDA label notes that volume depletion should be corrected before initiating therapy, and the drug should be used cautiously with diuretics. [1]

Euglycemic Diabetic Ketoacidosis

Euglycemic DKA (blood glucose <250 mg/dL with elevated ketones and acidosis) is a rare but serious risk with all SGLT2 inhibitors. [6] It can occur in adolescents with T2D who also have some degree of residual insulin deficiency. Caregivers should call 911 or go to an emergency room immediately if the teen has:

• Nausea, vomiting, and abdominal pain
• Difficulty breathing
• Unusual fatigue or confusion

...even if the home glucometer reads a "normal" blood sugar. Euglycemic DKA is missed precisely because the blood glucose is not dramatically elevated.

Missed Dose Protocol

If the teen misses a morning dose and remembers the same day, give the missed dose as soon as possible. If it is already the next morning (or nearly so), skip the missed dose and resume the regular schedule. Never give two doses on the same day to compensate for a missed one. [1]

Consistent daily dosing matters for this drug class. A single missed dose rarely causes a clinically significant glucose spike, but habitual skipping will reduce HbA1c efficacy. The TODAY study found that youth-onset T2D shows faster glycemic deterioration than adult-onset disease, [5] so consistent adherence carries more weight for this age group than it might for an adult starting on an SGLT2 inhibitor in their 50s.

Caregiver Adherence Framework for Adolescents on Empagliflozin

1. Pair the tablet with a fixed morning anchor (breakfast, toothbrushing, or phone alarm).
2. Keep the bottle visible but secured from younger siblings or pets.
3. Use a weekly pill organizer to make missed doses immediately visible.
4. Before school trips, sports travel, or vacations, pack enough tablets plus a two-day buffer.
5. If the teen is handling their own dose, a caregiver spot-check of the pill organizer weekly maintains oversight without undermining adolescent autonomy.

Contraindications and Situations That Require Pausing the Drug

Empagliflozin is contraindicated when eGFR falls below 30 mL/min/1.73 m² or when the patient is on dialysis. [1] Caregivers should ensure annual (or more frequent) kidney function monitoring is scheduled.

The drug should be held before any procedure requiring iodinated contrast dye, because contrast nephropathy can acutely drop eGFR. Standard practice is to hold SGLT2 inhibitors 48 hours before contrast and restart only after confirmed renal recovery. [8]

Surgical Procedures and Fasting

The American Diabetes Association (ADA) 2024 Standards of Care state: "SGLT2 inhibitors should be held for at least 3 to 4 days before elective surgical procedures due to the risk of perioperative euglycemic DKA." [9] Caregivers should inform every surgical team, dentist performing sedation, or anesthesiologist that their teenager takes empagliflozin.

Illness (Sick-Day Rules)

During febrile illness or prolonged vomiting and diarrhea, the prescriber may recommend temporarily holding empagliflozin to prevent dehydration and DKA. This is not a universal rule; it depends on the teen's overall insulin and glucose management plan. Always call the prescriber before stopping the drug during illness rather than making that decision independently.

Monitoring: What Labs and Checkups the Teen Needs

Standard monitoring for adolescents on empagliflozin includes:

• HbA1c: every 3 months until at goal, then every 3 to 6 months.
• eGFR and serum creatinine: at baseline, then annually or more often if there is a history of kidney disease.
• Urine microalbumin-to-creatinine ratio: annually, per ADA Standards of Care. [9]
• Blood pressure: at each visit, because SGLT2 inhibitors produce a modest 2 to 4 mmHg reduction in systolic blood pressure in adults. [3] This is generally beneficial, but hypotension is possible in a lean adolescent on concurrent antihypertensive therapy.
• Genital and urinary symptom review: at every clinic visit.

The ADA's 2024 pediatric glycemic targets recommend an HbA1c goal of <7% for most adolescents with T2D if achievable without significant hypoglycemia. [9]

Storage and Handling of Jardiance Tablets

Store empagliflozin tablets at controlled room temperature: 68 to 77°F (20 to 25°C). Brief excursions to 59 to 86°F (15 to 30°C) are acceptable during transport. [1] Keep the bottle tightly closed and away from moisture. Bathroom medicine cabinets, humid and sometimes hot, are poor storage locations.

Do not store tablets in a car glove compartment, particularly in summer months, when interior car temperatures may exceed 120°F.

Expired tablets should be disposed of through an FDA-approved drug take-back program. If no take-back program is available, mixing the tablets with an undesirable substance (coffee grounds, dirt) in a sealed bag before placing in household trash is the FDA-recommended disposal method for medications not on the FDA flush list. [10]

Talking to Your Teenager About Empagliflozin

Adolescents who understand why they are taking a medication show better adherence than those who receive only instructions. A brief explanation at the teen's level can help.

A useful framing: "This pill helps your kidneys flush out extra sugar through your urine before it can build up in your blood. You'll pee a little more, and you might notice a slightly sweet smell to your urine. That means the medicine is working."

Clinicians and caregivers should address three common adolescent concerns directly:

• "Will this make me gain weight?" SGLT2 inhibitors typically produce modest weight reduction (1 to 3 kg in adults) due to caloric loss through glucosuria. [3] This is generally considered neutral to positive.
• "Will I get infections all the time?" Not necessarily. Good hygiene habits substantially reduce the risk, and most infections are mild and treatable.
• "Do I still have to watch what I eat?" Yes. Empagliflozin reduces blood glucose but does not replace dietary management. The ADA recommends medical nutrition therapy as a concurrent intervention for all adolescents with T2D. [9]

When to Call the Prescriber Immediately

Caregivers should contact the prescribing clinician or seek emergency care if the teen experiences:

• Symptoms of DKA: nausea, vomiting, abdominal pain, rapid breathing, fruity breath odor, even with a "normal" glucose reading.
• Signs of a severe genital or urinary infection spreading to the kidneys (fever, chills, flank pain).
• Fournier's gangrene warning signs: severe pain, swelling, or redness in the genital or perineal area. This is an extremely rare but life-threatening necrotizing fasciitis reported in postmarketing data with SGLT2 inhibitors. [1]
• Sudden, significant decrease in urine output (possible acute kidney injury).
• Orthostatic dizziness, fainting, or rapid heart rate suggesting significant dehydration.

Do not wait for the next scheduled clinic visit for any of the above. These are same-day or emergency situations.